Oncologists moot copayments to boost access to innovative treatment for breast cancer: public patients can pay a portion (perhaps 30%-50%) of the drug cost. New targeted and immunotherapies are showing promise, especially for early-stage breast cancer. https://codeblue.galencentre.org/2025/02/experts-suggest-copay-for-innovative-breast-cancer-treatments/